Premarket Decliner
GLSI Greenwich Lifesciences53.60+3.10+6.1%
Premarket:48.20-5.40 (-10.1%)
REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
Business WireMon, 12-Apr 5:52 AM
After Hours Decliner
After Hours:51.40-2.20 (-4.1%)
Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
Business WireFri, 9-Apr 5:00 AM
After Hours:51.20-2.40 (-4.5%)
Premarket Gainer
GLSI Greenwich Lifesciences5.20-0.19-3.6%
Premarket:28.00+22.80 (+438.6%)
Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer
Business WireWed, 9-Dec 9:05 AM
